← Leaderboards
Tony E Godfrey
University Of Pittsburgh At Pittsburgh
$9,226,279
Attributed
$11,079,802
Total exposure
10
Grants
7
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.8M · FY2005–23$2M$1.5M$1M$500K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
Funding mix
By agency
NIH$11,079,802 · 10
By mechanism
R01$6,706,331 · 4
R44$2,230,363 · 1
R21$1,092,891 · 3
T32$1,050,217 · 1
P50$0 · 1
Top collaborators
- Daniel G. Remick4 shared
- Kristina Fontanez3 shared
- Tom B Morrison2 shared
- James C Willey2 shared
Most similar at University Of Pittsburgh At Pittsburgh
Same institution · by research overlap
- Joel S Greenberger$22,565,586
- James D Luketich$2,960,577
- Antonia Rogado Sepulveda$2,732,114
- Jill M Siegfried$10,296,579
- Steven J Hughes$2,808,835
Others in their field
Top investigators on “Base”
- Sonia M Thomas · Research Triangle Institute$700,865,642
- David Heimbrook · Leidos Biomedical Research, Inc.$613,567,095
- David Divins · Consortium For Ocean Leadership, Inc$609,772,544
- Larry Arthur$521,411,998
- Leonard Freedman · Leidos Biomedical Research, Inc.$515,995,429
- Margaret Juliana McElrath · Fred Hutchinson Cancer Center$507,042,060
Research focus
BaseTumorMolecularMalignant NeoplasmsLeadDiagnosisStagingGenomicsBiopsySpecimenFundingSamplingEsophageal AdenocarcinomaGastroesophageal Reflux DiseaseBarrett EsophagusGeneticIncidencePrognosticSurvival RateFutureDetectionGenesNeoadjuvant TherapyCells
Grant awards (37)
Impact of Biological, Clinical, and Social Determinants on Trauma and Trauma Outcomes$264,518
T32 · FY2023 · GM · contact PI
Impact of Biological, Clinical, and Social Determinants on Trauma and Trauma Outcomes$250,865
T32 · FY2022 · GM · contact PI
Development of diagnostic and prognostic tests for esophageal adenocarcinoma$240,649
R01 · FY2022 · CA · contact PI
Custom assays for personalized, longitudinal monitoring of circulating tumor DNA using PIPSenSeq$825,632
R44 · FY2021 · CA
Immunobiology of Trauma$235,294
T32 · FY2021 · GM · contact PI
Development of diagnostic and prognostic tests for esophageal adenocarcinoma$134,246
R01 · FY2021 · CA · contact PI
Custom assays for personalized, longitudinal monitoring of circulating tumor DNA using PIPSenSeq$1,105,490
R44 · FY2020 · CA
Development of diagnostic and prognostic tests for esophageal adenocarcinoma$385,317
R01 · FY2020 · CA · contact PI
Immunobiology of Trauma$299,540
T32 · FY2020 · GM · contact PI
Development of diagnostic and prognostic tests for esophageal adenocarcinoma$428,383
R01 · FY2019 · CA · contact PI
Custom assays for personalized, longitudinal monitoring of circulating tumor DNA using PIPSenSeq$299,241
R44 · FY2019 · CA
Development of diagnostic and prognostic tests for esophageal adenocarcinoma$603,464
R01 · FY2018 · CA · contact PI
Development of diagnostic and prognostic tests for esophageal adenocarcinoma$646,502
R01 · FY2017 · CA · contact PI
Feasibility of Molecular Cytology for the Management of Barrett's Esophagus$162,114
R21 · FY2016 · CA · contact PI
Feasibility of Molecular Cytology for the Management of Barrett's Esophagus$214,371
R21 · FY2015 · CA · contact PI
Innovative approach to cancer detection and treatment monitoring$169,886
R21 · FY2014 · CA · contact PI
Innovative approach to cancer detection and treatment monitoring$226,670
R21 · FY2013 · CA · contact PI
Biomarkers for Esophageal Cancer Progression and Prognosis$189,807
R01 · FY2012 · CA · contact PI
Biomarkers for Esophageal Cancer Progression and Prognosis$164,265
R01 · FY2012 · CA · contact PI
Biomarkers for Esophageal Cancer Progression and Prognosis$308,210
R01 · FY2011 · CA · contact PI
Biomarkers for Esophageal Cancer Progression and Prognosis$317,743
R01 · FY2010 · CA · contact PI
Biomarkers for Esophageal Cancer Progression and Prognosis$317,743
R01 · FY2009 · CA · contact PI
Biomarkers for Esophageal Cancer Progression and Prognosis$188,471
R01 · FY2009 · CA · contact PI
Standardized NanoArray PCR for Gene Expression Profiling of Lung Cancer$70,600
R21 · FY2009 · CA
Biomarkers for Esophageal Cancer Progression and Prognosis$331,243
R01 · FY2008 · CA · contact PI
Standardized NanoArray PCR for Gene Expression Profiling of Lung Cancer$249,250
R21 · FY2008 · CA
Molecular Staging Of Lymph Nodes In Head And Neck Cancer$258,762
R01 · FY2007 · CA · contact PI
Molecular Detection of Occult Metastases in Lung Cancer$312,494
R01 · FY2006 · CA · contact PI
Molecular Staging Of Lymph Nodes In Head And Neck Cancer$266,490
R01 · FY2006 · CA · contact PI
Molecular Detection of Occult Metastases in Lung Cancer$320,014
R01 · FY2005 · CA
Molecular Detection of Occult Metastases in Lung Cancer$337,389
R01 · FY2004 · CA
Molecular Staging Of Lymph Nodes In Head And Neck Cancer$300,447
R01 · FY2004 · CA
Molecular Staging Of Lymph Nodes In Head And Neck Cancer$1
R01 · FY2004 · CA
Molecular Detection of Occult Metastases in Lung Cancer$331,525
R01 · FY2003 · CA
Molecular Detection of Occult Metastases in Lung Cancer$323,166
R01 · FY2002 · CA
CORE--GENOMICS$0
P50 · FY2002 · CA
CORE--GENOMICS$0
P50 · FY2001 · CA